The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 30, 2015

Filed:

Jun. 28, 2013
Applicant:

Novo Nordisk A/s, Bagsvaerd, DK;

Inventors:

Jane Spetzler, Broenshoej, DK;

Lauge Schaeffer, Lyngby, DK;

Jesper Lau, Farum, DK;

Thomas Kruse, Herlev, DK;

Patrick William Garibay, Holte, DK;

Soeren Oestergaard, Broenshoej, DK;

Steffen Reedtz-Runge, Frederiksberg, DK;

Henning Thoegersen, Farum, DK;

Assignee:

Novo Nordisk A/S, Bagsvaerd, DK;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 1/107 (2006.01); C07K 14/00 (2006.01); C07K 14/575 (2006.01); C07K 14/605 (2006.01); A61K 38/16 (2006.01); A61K 38/22 (2006.01); A61K 38/26 (2006.01); A61K 38/17 (2006.01); A61K 47/48 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/001 (2013.01); C07K 14/00 (2013.01); C07K 14/575 (2013.01); A61K 38/16 (2013.01); A61K 38/17 (2013.01); A61K 38/22 (2013.01); A61K 38/26 (2013.01); A61K 47/48 (2013.01); A61K 47/48007 (2013.01); A61K 47/48023 (2013.01); A61K 47/48169 (2013.01); A61K 38/00 (2013.01); A61K 47/48038 (2013.01); A61K 47/48046 (2013.01); A61K 47/48061 (2013.01); A61K 47/48215 (2013.01); C07K 14/57563 (2013.01); C07K 14/605 (2013.01);
Abstract

The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogs thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B-C-, or A-B-C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration.


Find Patent Forward Citations

Loading…